Fig. 5.
Fig. 5. Engraftment of drug-resistant human PBPCs in NOD/Scid mice. A representative highly engrafted NOD/Scid mouse transplanted with 400 × 103 drug-resistant PBPCs and 1 × 106 L87/4 stromal cells was analyzed 6 weeks after transplantation by three-color flow cytometry. The percentage of positive cells per each quadrant is indicated. Cells were stained with Cy-C–labeled anti-human CD45 antibody and compared with cells stained with Cy-C isotype control. Dead cells were excluded by their intense 7AAD staining, and viable cells were gated according to their human CD45 expression (horizontal line in the histogram). Sixty-one percent of CD45+ human cells were present in the BM of this mice. As shown in the contour plots, among these CD45+ cells 19% (corresponding to 11% of all cells) were CD13+ (myeloid), 53% (corresponding to 32% of all cells) were CD19+ (lymphoid), 1% were CD34+/CD38− (early hematopoietic progenitors), 2% were CD61+ (megakaryocytic), and 5% were glycophorin A+ (erythroid).

Engraftment of drug-resistant human PBPCs in NOD/Scid mice. A representative highly engrafted NOD/Scid mouse transplanted with 400 × 103 drug-resistant PBPCs and 1 × 106 L87/4 stromal cells was analyzed 6 weeks after transplantation by three-color flow cytometry. The percentage of positive cells per each quadrant is indicated. Cells were stained with Cy-C–labeled anti-human CD45 antibody and compared with cells stained with Cy-C isotype control. Dead cells were excluded by their intense 7AAD staining, and viable cells were gated according to their human CD45 expression (horizontal line in the histogram). Sixty-one percent of CD45+ human cells were present in the BM of this mice. As shown in the contour plots, among these CD45+ cells 19% (corresponding to 11% of all cells) were CD13+ (myeloid), 53% (corresponding to 32% of all cells) were CD19+ (lymphoid), 1% were CD34+/CD38 (early hematopoietic progenitors), 2% were CD61+ (megakaryocytic), and 5% were glycophorin A+ (erythroid).

Close Modal

or Create an Account

Close Modal
Close Modal